Diabetes, obesity & metabolism
Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.
Roman Drai, Gagik Galstyan, Tatiana Karonova, Ekaterina Protsenko, Tatyana Parfenova, Anna Arefeva, Iuliia Matvienko, Dmitrii Iliushchenko, Igor Makarenko
Published: 202510.1111/dom.70360
Abstract
AIMS: To evaluate the immunogenicity, efficacy, and safety of a biosimilar insulin glulisine candidate (T-Glu) compared to the reference product (R-Glu) in patients with type 1 diabetes mellitus (T1DM). MATERIALS AND METHODS: In this phase III, rando…
Preview only. Read the full abstract at the source